Last reviewed · How we verify
Ipratropium Bromide HFA Inhalation Aerosol
Anticholinergic agent that inhibits muscarinic acetylcholine receptors
Anticholinergic agent that inhibits muscarinic acetylcholine receptors Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | Ipratropium Bromide HFA Inhalation Aerosol |
|---|---|
| Also known as | Atrovent |
| Sponsor | Pearl Therapeutics, Inc. |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Ipratropium bromide is a non-selective muscarinic receptor antagonist that inhibits the action of acetylcholine at muscarinic receptors in the lungs, thereby reducing bronchospasm and mucus secretion.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Cough
- Dysphonia
- Headache
Key clinical trials
- A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (PHASE2)
- Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: